

AS Sub B1  
1. (Amended) A pharmaceutical composition comprising a neuroprotectant amount of pGLU-GLU-PRO-NH<sub>2</sub> as an active ingredient.

Q6  
3. (Amended) A pharmaceutical composition comprising pGLU-GLU-PRO-NH<sub>2</sub> and N-tert-Butyl- $\alpha$ -(2-sulfohenyl)nitron as active ingredients.

Q7  
5. (Amended) A pharmaceutical composition comprising pGLU-GLU-PRO-NH<sub>2</sub> and one or more nitrones as active ingredients.

Q8 Sub B2  
7. (Amended) A method of treating neurological diseases and injuries comprising administering to a patient a composition comprising a therapeutically effective amount of pGLU-GLU-PRO-NH<sub>2</sub> as an active ingredient under time and conditions to treat said disease.

Q9 Sub B3  
10. (Amended) A method of treating neurological diseases and injuries comprising administering to a patient a composition comprising a therapeutically effective amount of (a) pGLU-GLU-PRO-NH<sub>2</sub> and (b) N-tert-Butyl- $\alpha$ -(2-sulfohenyl) nitron or a free radical scavenging nitron that enhances the effects of pGLU-GLU-PRO-NH<sub>2</sub> under time and conditions to treat said disease.

Please add the following claim:

Rule 126  
Q10 Sub B4  
13  
11. (New) A method of preventing neurological diseases and injuries comprising administering to a patient a composition comprising a therapeutically effective amount of pGLU-GLU-PRO-NH<sub>2</sub> as an active ingredient under time and conditions to treat said disease.

Add B5